US medtech prices constant, "highly competitive", 15-year study says
This article was originally published in Clinica
A study carried out for the US medical device and diagnostics industry has found that, over the past 15 years, the cost of medical technology to the nation has remained steady and the price of the technology has been highly competitive.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.